论文部分内容阅读
氯吡格雷是临床常用抗血小板聚集药物,其疗效显著,但存在明显的个体差异。该差异可导致氯吡格雷抗血小板聚集药效下降而引起心血管缺血事件,或使其药效增强而引起出血等不良反应。细胞色素P4502C19*17(CYP2C19*17)基因突变可使代谢酶活性增强,氯吡格雷活性代谢产物暴露增加,使其药效增强。本文系统地综述了近几年国内外CYP2C19*17基因突变与氯吡格雷的疗效关系的研究,为临床个体化用药提供相关参考依据。
Clopidogrel is commonly used in clinical anti-platelet aggregation drugs, the effect is significant, but there are significant individual differences. The difference can lead to clopidogrel antiplatelet aggregation decreased efficacy caused by cardiovascular events, or to enhance its efficacy caused by bleeding and other adverse reactions. Cytochrome P4502C19 * 17 (CYP2C19 * 17) gene mutation can enhance the activity of metabolic enzymes, clopidogrel active metabolite increased exposure, to enhance its efficacy. This article systematically reviewed the CYP2C19 * 17 gene mutations in recent years at home and abroad and the relationship between the efficacy of clopidogrel study for the clinical reference to provide personalized reference.